WO2001062925A3 - 103p2d6: tissue specific protein highly expressed in various cancers - Google Patents

103p2d6: tissue specific protein highly expressed in various cancers Download PDF

Info

Publication number
WO2001062925A3
WO2001062925A3 PCT/US2001/005996 US0105996W WO0162925A3 WO 2001062925 A3 WO2001062925 A3 WO 2001062925A3 US 0105996 W US0105996 W US 0105996W WO 0162925 A3 WO0162925 A3 WO 0162925A3
Authority
WO
WIPO (PCT)
Prior art keywords
highly expressed
expressed
specific protein
tissue specific
various cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/005996
Other languages
French (fr)
Other versions
WO2001062925A2 (en
Inventor
Arthur B Raitano
Daniel E H Afar
Gazelle Shiva Rastegar
Steve Chappell Mitchell
Rene S Hubert
Pia M Challita-Eid
Mary Faris
Aya Jakobovits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Priority to AU2001241742A priority Critical patent/AU2001241742B8/en
Priority to EP01913024A priority patent/EP1257644B1/en
Priority to CA002400443A priority patent/CA2400443A1/en
Priority to DE60130541T priority patent/DE60130541T2/en
Priority to IL15133501A priority patent/IL151335A0/en
Priority to AU4174201A priority patent/AU4174201A/en
Publication of WO2001062925A2 publication Critical patent/WO2001062925A2/en
Publication of WO2001062925A3 publication Critical patent/WO2001062925A3/en
Priority to IL151335A priority patent/IL151335A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A novel gene (designated 103P2D6) and its encoded protein are described. 103P2D6 is not expressed in normal adult tissue, but is highly expressed in prostate tissue xenografts, providing evidence that it is turned on in prostate cancer. 103P2SD6 is also expressed in some fetal tissues, and in breast, bladder, lung, bone, colon, pancreatic, testicular, cervical and ovarian cancers. Consequently, 103P2D6 provides a diagnostic and/or therapeutic target for cancers, and the 103P2D6 gene or fragment thereof, or its encoded protein or a fragment thereof can be used to elicit an immune response.
PCT/US2001/005996 2000-02-24 2001-02-26 103p2d6: tissue specific protein highly expressed in various cancers Ceased WO2001062925A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2001241742A AU2001241742B8 (en) 2000-02-24 2001-02-26 103P2D6: tissue specific protein highly expressed in various cancers
EP01913024A EP1257644B1 (en) 2000-02-24 2001-02-26 103p2d6: tissue specific protein highly expressed in various cancers
CA002400443A CA2400443A1 (en) 2000-02-24 2001-02-26 103p2d6: tissue specific protein highly expressed in various cancers
DE60130541T DE60130541T2 (en) 2000-02-24 2001-02-26 TISSUE SPECIFIC PROTEIN 103P2D6, STRONG EXPRESSED IN DIFFERENT CANCER TYPES
IL15133501A IL151335A0 (en) 2000-02-24 2001-02-26 103p2d6: tissue specific protein highly expressed in various cancers
AU4174201A AU4174201A (en) 2000-02-24 2001-02-26 103p2d6: tissue specific protein highly expressed in various cancers
IL151335A IL151335A (en) 2000-02-24 2002-08-19 103p2d6: tissue specific protein highly expressed in various cancers

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18455800P 2000-02-24 2000-02-24
US60/184,558 2000-02-24
US21885600P 2000-07-13 2000-07-13
US60/218,856 2000-07-13

Publications (2)

Publication Number Publication Date
WO2001062925A2 WO2001062925A2 (en) 2001-08-30
WO2001062925A3 true WO2001062925A3 (en) 2002-03-28

Family

ID=26880247

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/005996 Ceased WO2001062925A2 (en) 2000-02-24 2001-02-26 103p2d6: tissue specific protein highly expressed in various cancers

Country Status (7)

Country Link
EP (1) EP1257644B1 (en)
AT (1) ATE373711T1 (en)
AU (2) AU2001241742B8 (en)
CA (1) CA2400443A1 (en)
DE (1) DE60130541T2 (en)
IL (2) IL151335A0 (en)
WO (1) WO2001062925A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1212343A4 (en) * 1999-09-03 2004-11-03 Human Genome Sciences Inc 52 HUMAN SECRETED PROTEINS
US7534417B2 (en) 2000-02-24 2009-05-19 Agensys, Inc. 103P2D6: tissue specific protein highly expressed in various cancers
WO2003020954A2 (en) 2001-08-31 2003-03-13 Agensys, Inc. 205p1b5 in treatment and detection of cancer
EP3641804A1 (en) * 2017-06-22 2020-04-29 Institut Gustave Roussy Human endogenous retroviral protein
US20230287067A1 (en) * 2020-01-21 2023-09-14 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Human immunogenic epitopes of hemo and hhla2 human endogenous retroviruses (hervs)
DE102020125457A1 (en) * 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidated peptides and their deamidated counterparts presented by HLA-A*02 molecules for use in immunotherapy against various types of cancer
AU2024296108A1 (en) * 2023-07-20 2026-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Identification of sequence variants of the ervmer34-1 sequence family and use in anti-cancer therapies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045435A2 (en) * 1997-04-10 1998-10-15 Genetics Institute, Inc. SECRETED EXPRESSED SEQUENCE TAGS (sESTs)
EP1074617A2 (en) * 1999-07-29 2001-02-07 Helix Research Institute Primers for synthesising full-length cDNA and their use
WO2001018022A1 (en) * 1999-09-03 2001-03-15 Human Genome Sciences, Inc. 52 human secreted proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045435A2 (en) * 1997-04-10 1998-10-15 Genetics Institute, Inc. SECRETED EXPRESSED SEQUENCE TAGS (sESTs)
EP1074617A2 (en) * 1999-07-29 2001-02-07 Helix Research Institute Primers for synthesising full-length cDNA and their use
WO2001018022A1 (en) * 1999-09-03 2001-03-15 Human Genome Sciences, Inc. 52 human secreted proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 2 August 1999 (1999-08-02), XP002184242 *
DATABASE EMBL 2 July 1995 (1995-07-02), XP002184240 *
DATABASE EMBL 22 June 1995 (1995-06-22), XP002184241 *
DATABASE EMBL 9 February 2000 (2000-02-09), XP002184509 *
GELUK A. ET AL.: "HLA-DR3 molecules can bind peptides carrying two alternative specific submotifs", JOURNAL OF IMMUNOLOGY, vol. 152, 1994, pages 5742 - 5748, XP002184475 *

Also Published As

Publication number Publication date
AU2001241742B2 (en) 2006-04-06
EP1257644B1 (en) 2007-09-19
AU2001241742B8 (en) 2006-05-11
DE60130541T2 (en) 2008-06-19
IL151335A (en) 2009-09-01
AU4174201A (en) 2001-09-03
ATE373711T1 (en) 2007-10-15
WO2001062925A2 (en) 2001-08-30
IL151335A0 (en) 2003-04-10
CA2400443A1 (en) 2001-08-30
EP1257644A2 (en) 2002-11-20
DE60130541D1 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
IL147902A0 (en) C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2002016413A3 (en) Cripto tumour polypeptide
WO2002046477A3 (en) Endogenous retroviruses up-regulated in prostate cancer
WO2002010382A3 (en) Trp8, trp9 and trp10, markers for cancer
AU2002338852A1 (en) Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
WO2005054295A8 (en) Therapeutic and diagnostic anti-hsp 70 antibodies
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
IL151335A (en) 103p2d6: tissue specific protein highly expressed in various cancers
WO2003026494A3 (en) Galectins-1-and-4 in tumor development
WO2006027693A3 (en) Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis
WO2001079557A3 (en) Gtp-binding protein useful in treatment and detection of cancer
EP0839908A3 (en) A novel human ETS family member, ELF3
EP2365081A3 (en) 13 Transmembrane protein expressed in prostate cancer
AU2002364501A1 (en) Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
WO2001055391A3 (en) 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
WO2001059110A3 (en) 34p3d7: a tissue specific protein highly expressed in prostate cancer
WO2001059115A3 (en) 83p5g4: a tissue specific protein highly expressed in prostate cancer
WO2000035469A3 (en) hCG THERAPY FOR THE TREATMENT OF BREAST CANCER
WO2003020954A3 (en) 205p1b5 in treatment and detection of cancer
WO2001096391A3 (en) 55p4h4: gene expressed in various cancers
AU2002365104A1 (en) Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof
WO2001090157A8 (en) 98p7c3: homeodomain protein highly expressed in various cancers
WO2000061610A3 (en) Prostate-restricted gene 30p3c8 expressed in prostate cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2400443

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 151335

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2001241742

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001913024

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001913024

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2001913024

Country of ref document: EP